Eloralintide vs Retatrutide | GLP-1R/GCGR vs Triple Agonist | QSC
Eloralintide vs Retatrutide
GLP-1R/GCGR Dual Agonist vs Triple Agonist — Mechanism, Data & Research Application Comparison | QSC
Factor
Eloralintide
Retatrutide
Class
Dual GLP-1R/GCGR Agonist
Triple Agonist
Mechanism
GLP-1R + GCGR co-agonism
GLP-1R+GIPR+GCGR triple agonist
Best Trial Result
~10–11% wt loss · ~40–50% liver fat ↓
−24.2% (Phase 2, 48w)
NASH / Liver Data
✓ Phase 2 — direct GCGR/CPT1A
Phase 2 data (GCGR+GIPR)
GCGR Component
✓ Direct hepatic fat oxidation
✓
At QSC
✓ In stock — first mover
✓ In stock
Research Analysis: Retatrutide adds GIPR to the GLP-1R+GCGR of eloralintide — making it a triple agonist. This produces the highest weight loss efficacy in clinical trial history (−24.2%). For isolated GCGR mechanism research without GIPR confounds, eloralintide is the cleaner tool — GIPR has independent adipose and hypothalamic effects that complicate hepatic mechanism attribution. For maximum efficacy and triple receptor pharmacology, retatrutide. Both available at QSC.
What is the difference between eloralintide and Retatrutide?
Eloralintide is a dual GLP-1R/GCGR co-agonist; Retatrutide is a Triple Agonist. The key mechanistic difference is the presence or absence of GCGR: eloralintide’s GCGR agonism drives direct hepatic CPT1A-mediated fat oxidation — independent of body weight loss. Retatrutide adds GIPR to the GLP-1R+GCGR of eloralintide — making it a triple agonist. This produces the highest weight loss efficacy in clinical trial history (−24.2%). For isolated GCGR mechanism research without GIPR confounds, eloralintide is the
Which is better for NASH research: eloralintide or Retatrutide?
For research specifically targeting direct hepatic fat oxidation via GCGR/CPT1A, eloralintide is the dedicated tool — Phase 2 data shows ~40–50% liver fat reduction, disproportionate to ~10–11% weight loss. Both compounds have direct GCGR mechanisms for comparison.
Are both eloralintide and Retatrutide available at QSC?
Yes — both eloralintide and Retatrutide are available at QSC (qscpeptide.com) at ≥99% HPLC purity with Janoshik independent COA verification. US Domestic Warehouse, 2–4 business day delivery. Researchers can source both compounds from one verified supplier for comparative protocols.
Research Use Only: Eloralintide is sold by QSC strictly for in vitro laboratory research purposes only. Not for human or veterinary use. Not FDA approved for clinical use.
